

Additional file 2




Figure. Changes in C-reactive protein after switching to cabotegravir plus rilpivirine. The changes in C-reactive protein after switching to cabotegravir plus rilpivirine in all patients (A), TAF-based regimen group (B), and DTG-based regimen group (C), respectively, are shown. Baseline, at the start of oral-lead-in; month 0, at the start of injectable cabotegravir plus rilpivirine. TAF, tenofovir alafenamide; DTG, dolutegravir